Centene Co. (NYSE:CNC) Shares Sold by Warther Private Wealth LLC

Warther Private Wealth LLC cut its stake in Centene Co. (NYSE:CNC) by 35.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,856 shares of the company’s stock after selling 2,114 shares during the period. Warther Private Wealth LLC’s holdings in Centene were worth $234,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of CNC. Harris Associates L P increased its stake in Centene by 5.7% in the 3rd quarter. Harris Associates L P now owns 26,314,183 shares of the company’s stock valued at $1,980,932,000 after purchasing an additional 1,420,825 shares in the last quarter. State Street Corp raised its stake in shares of Centene by 0.5% during the 3rd quarter. State Street Corp now owns 23,468,159 shares of the company’s stock worth $1,766,683,000 after buying an additional 111,654 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Centene by 3.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,768,534 shares of the company’s stock worth $434,255,000 after buying an additional 194,566 shares in the last quarter. Hotchkis & Wiley Capital Management LLC grew its stake in Centene by 15.4% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,203,049 shares of the company’s stock valued at $241,126,000 after acquiring an additional 428,100 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Centene by 693.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,705,936 shares of the company’s stock valued at $103,346,000 after acquiring an additional 1,490,935 shares in the last quarter. 93.63% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Centene news, Director Thomas Greco bought 17,000 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were acquired at an average cost of $59.75 per share, with a total value of $1,015,750.00. Following the completion of the transaction, the director now owns 19,309 shares in the company, valued at $1,153,712.75. The trade was a 736.25 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II purchased 5,000 shares of Centene stock in a transaction that occurred on Friday, December 13th. The stock was acquired at an average cost of $58.86 per share, with a total value of $294,300.00. Following the acquisition, the director now directly owns 23,000 shares of the company’s stock, valued at $1,353,780. The trade was a 27.78 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 23,693 shares of company stock worth $1,409,954 over the last quarter. 0.33% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently commented on CNC. Wells Fargo & Company lowered their price target on shares of Centene from $91.00 to $90.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Stephens dropped their price target on Centene from $75.00 to $73.00 and set an “equal weight” rating for the company in a research report on Friday, December 13th. Truist Financial decreased their price objective on Centene from $89.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. StockNews.com downgraded shares of Centene from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 6th. Finally, Oppenheimer decreased their price target on shares of Centene from $95.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday, December 13th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $81.31.

Centene Stock Performance

Centene stock opened at $57.36 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.11 and a quick ratio of 1.10. Centene Co. has a 12 month low of $55.03 and a 12 month high of $81.42. The company has a market cap of $28.96 billion, a price-to-earnings ratio of 9.19, a price-to-earnings-growth ratio of 0.79 and a beta of 0.45. The stock’s 50-day moving average is $61.21 and its 200-day moving average is $66.91.

Centene (NYSE:CNC) last released its quarterly earnings data on Tuesday, February 4th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.31. The company had revenue of $40.81 billion during the quarter, compared to the consensus estimate of $38.78 billion. Centene had a net margin of 2.03% and a return on equity of 13.85%. Centene’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.45 earnings per share. Equities analysts anticipate that Centene Co. will post 6.97 earnings per share for the current year.

Centene Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.